These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24531224)

  • 41. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
    Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
    Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
    Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X
    Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
    Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
    Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes.
    Li S; Xu H; Cui S; Wu F; Zhang Y; Su M; Gong Y; Qiu S; Jiao Q; Qin C; Shan J; Zhang M; Wang J; Yin Q; Xu M; Liu X; Wang R; Zhu L; Li J; Xu Y; Jiang H; Zhao Z; Li J; Li H
    J Med Chem; 2016 Jul; 59(14):6772-90. PubMed ID: 27396490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
    Huan Y; Jiang Q; Liu JL; Shen ZF
    J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.
    Tanwar O; Tanwar L; Shaquiquzzaman M; Alam MM; Akhter M
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3447-51. PubMed ID: 24948564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors.
    Khalaf RA; Sabbah D; Al-Shalabi E; Al-Sheikh I; Albadawi G; Abu Sheikha G
    Curr Comput Aided Drug Des; 2018; 14(2):142-151. PubMed ID: 29521244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X; Han L; Zhou J; Zhang H; Li Q
    Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.
    Fang Y; Zhang S; Wu W; Liu Y; Yang J; Li Y; Li M; Dong H; Jin Y; Liu R; Yang Z
    Bioorg Chem; 2020 Jan; 94():103390. PubMed ID: 31662212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.
    Rea D; Van Elzen R; De Winter H; Van Goethem S; Landuyt B; Luyten W; Schoofs L; Van Der Veken P; Augustyns K; De Meester I; Fülöp V; Lambeir AM
    Eur J Med Chem; 2017 Oct; 139():482-491. PubMed ID: 28826083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.
    Nitta A; Fujii H; Sakami S; Satoh M; Nakaki J; Satoh S; Kumagai H; Kawai H
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7036-40. PubMed ID: 23072865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
    Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
    Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK
    Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.